Today’s announcement that AbbVie will invest $380 million to build two new active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago campus marks a significant milestone for U.S. pharmaceutical innovation and domestic manufacturing leadership. The project will incorporate advanced manufacturing technologies, including artificial intelligence (AI), to support the production of next-generation neuroscience and obesity medicines. Construction is slated to begin in spring 2026 with both facilities expected to be fully operational in 2029. In support of the expansion, AbbVie plans to hire 300 new employees, including engineers, scientists, manufacturing operators and lab technicians.
Download now